Search

Displaying results 1431 - 1440 of 1640 in total
  1. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  2. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor … [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of

  3. Drug

    Edoxaban

    go.drugbank.com/drugs/DB09075
    ApprovedInvestigational

    In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will

  4. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving

  5. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    fragment C5a and its cognate C5aR receptor in AAV. … [A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin

    Categories: Complement 5a Receptor Antagonist
  6. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients.

  7. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum to...

  8. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as

    Categories: Integrin Receptor Antagonist
  9. Drug

    Homosalate

    go.drugbank.com/drugs/DB11064
    Approved

    Homosalate is an organic compound that belongs to salicylates. It is an ester formed from salicylic acid and 3,3,5-trimethylcyclohexanol, a derivative of cyclohexanol. Salicylates prevent direct skin exposure to the sun’s harmful rays by...

    Mixtures: Aloette Tan CC Cream, Wknd Underwater Sun Tan
  10. Target

    P2X purinoceptor 7

    go.drugbank.com/bio_entities/BE0009814
    TargetHumans

    ATP-gated nonselective transmembrane cation channel that requires high millimolar concentrations of ATP for activation (PubMed:17483156, PubMed:25281740, PubMed:9038151). Upon ATP binding, it rapidly opens to allow the influx of small ca...

    Synonyms: ATP receptor, P2Z receptor